Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

por Wallace, Daniel J, Strand, Vibeke, Merrill, Joan T, Popa, Serghei, Spindler, Alberto J, Eimon, Alicia, Petri, Michelle, Smolen, Josef S, Wajdula, Joseph, Christensen, Jared, Li, Cheryl, Diehl, Annette, Vincent, Michael S, Beebe, Jean, Healey, Paul, Sridharan, Sudhakar
Publicado 2017